Day: September 26, 2024

First award under UNICEF emergency tender to secure availability of mpox vaccines for AfricaCOPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak. Under the agreement, UNICEF will procure 1 million doses of the vaccine which includes the 500,000 doses that were committed by Gavi and announced on September 18, 2024. As part of Bavarian Nordics commitment to increase and prioritize its production capacity to fulfil the short- and medium-term demand, the Company will make all doses available for supply before the end of 2024 and will work with UNICEF and its partners to swiftly deliver the vaccines upon request. Paul Chaplin, President & CEO of Bavarian Nordic,...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, combined with improved performance in Travel Health, as well as other parts of the business, Bavarian Nordic now expects revenue between DKK 5,400 million and DKK 5,800 million and EBITDA between DKK 1,450 million and DKK 1,700 million. Revenue from the Travel Health business is now expected at approximately DKK 2,200 million, the Public Preparedness business between DKK 3,000 million and DKK 3,400 million and Other Revenue unchanged at approximately DKK 200 million. The Public Preparedness guidance is based on secured orders, as well as several smaller orders expected to be signed soon. The revenue interval represents uncertainty related to logistics...

Old Bethpage, New York, Sept. 26, 2024 (GLOBE NEWSWIRE) — Power REIT (NYSE-AMEX: PW and PW.PRA) (“Power REIT” or the “Trust”), today announced that it received a notice from the NYSE American LLC rescinding its letter dated September 3, 2024 (the “Deficiency Letter”). As previously disclosed, the Deficiency Letter stated that the Trust was not in compliance with the continued listing standards of the Exchange because the Trust was below compliance with Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”), requiring stockholders’ equity of $2.0 million or more if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. As part of evaluating a plan to comply with the NYSE American listing requirements, the Trust embarked on analysis of the accounting...

               Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET – Urteste S.A. (Warsaw Stock Exchange: URT),  a biotechnology company specializing in the development of breakthrough technology to detect cancer from urine samples, best known for its flagship project PANURI, a diagnostic test for pancreatic cancer. The company’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, and has high sensitivity and specificity, with results available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error.A proof-of-concept...

Stolt-Nielsen Limited to Present the Results for the Third Quarter of 2024 LONDON, September 26, 2024 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a presentation to discuss the Company’s unaudited results for the third quarter of 2024 on Wednesday, October 2, 2024 at 15:00 CEST (09:00 EDT, 14:00 BST). The presentation will be hosted by: –        Mr. Udo Lange – Chief Executive Officer, Stolt-Nielsen Limited –        Mr. Jens F. Grüner-Hegge – Chief Financial Officer, Stolt-Nielsen Limited –        Mr. Alex Ng – Vice President Strategy & Business Development, Stolt-Nielsen Limited For investors, analysts and journalists who wish to attend in person, the presentation is being held at SEB, Filipstad Brygge 1, 0252 Oslo, Norway. Those who wish to participate in the live presentation online...

PLANO, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), a pioneer in creating healthy and convenient protein snacks, announces the launch of High Steaks, an innovative brand dedicated to providing high-quality, high-protein, human-grade pet treats. Stryve Foods, known for air-dried meat snacks under the brands Stryve, Vacadillos, and Kalahari, is bringing their premium, high protein, 0g sugar, simple ingredient meat products to your pet. High Steaks human-grade pet treats, are the perfect on-the-go solution for an active, and healthy dog.High Steaks treats feature real, air-dried beef as the primary component. Each treat is formulated to deliver the essential proteins that pets need for energy, muscle development, and optimal health. The brand aims to meet the growing demand...

New HealthEquity research indicates employers who optimize HSA contribution strategies are more directly supporting their employees’ financial well-being DRAPER, Utah, Sept. 26, 2024 (GLOBE NEWSWIRE) — HealthEquity, Inc. (Nasdaq: HQY) (“HealthEquity”) today released research findings on how Health Savings Account (HSA) contribution strategies influence how employees participate in their HSA benefits. The qualitative and quantitative analysis included a sample of nearly 2,000 HealthEquity clients and more than 2 million HSA members. The analysis provides insight for employers who want to create impactful HSA benefit strategies that support their employees’ financial wellbeing. “Benefit leaders want employees to get the most out of their benefits — including HSAs — and fostering utilization is a constant challenge,” said...